GlassScriptPhysician profile
Luis Sabatini
NPI 1386632776
$3,624.83
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $773 · 2021: $1,160 · 2022: $942 · 2023: $114 · 2024: $78.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $192.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $492.76 | 2019-2022 | |
| Amarin Pharma, INC. | $459.49 | 2019-2021 | |
| Abbvie INC. | $412.51 | 2020-2024 | Dalvance, Avycaz |
| Bayer Healthcare Pharmaceuticals INC. | $305.42 | 2021-2022 | |
| Pfizer INC. | $229.22 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $185.95 | 2021-2022 | |
| Allergan, INC. | $185.55 | 2019-2020 | |
| Astellas Pharma US INC | $157.30 | 2019-2021 | |
| Lilly USA, LLC | $150.08 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $141.21 | 2019-2021 | |
| Amgen INC. | $118.21 | 2019-2021 | |
| Stryker Corporation | $110.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.58 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $76.58 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.03 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $60.13 | 2020-2023 | Proclaim |
| Glaxosmithkline, LLC. | $53.63 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $52.59 | 2021-2022 | |
| Almatica Pharma LLC | $42.66 | 2021-2022 | |
| Heartflow, INC. | $33.33 | 2022 | |
| Genentech USA, INC. | $31.61 | 2019-2021 | |
| Medtronic, INC. | $25.88 | 2022 | |
| Biogen, INC. | $19.90 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.78 | 2021 | |
| Philips North America LLC | $14.61 | 2022 | |
| Scilex Pharmaceuticals INC. | $14.38 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.15 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.96 | 2021 | |
| Shire North American Group INC | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Sabatini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.